Folks, if this does not enlighten you, then you have been de-selected by Darwin.
Jonathan Chow, MD, University, and colleagues concluded that aspirin was useful in keeping people off ventilators and preventing C****-** deaths. Here is a summary of their findings.
412 patients were included in the study
314 did not receive aspirin, 98 did.
The 98 patients who received aspirin were a combination of those who were already taking aspirin before hospitalization and those given it following hospitalization.
After adjusting for 8 confounders, the use of aspirin was associated with a 44% decrease in ventilation, a 43% decrease in ICU admission, and a 47% decrease in deaths (in the hospital).
There was no difference in serious bleeding between the two groups.
“The results of the study do not really surprise us because we know that C***D causes excess clot formation and we know that aspirin is a very potent blood thinner...so when you have a disease that causes clots and a medication that thins your blood, that may lead to the protective effects that we found.”
Jonathan Chow, M.D.
https://www.acsh.org/news/2021/06/15/aspirin-reduces-ventilation-and-deaths-hospitalized-c****-**-patients-15603PEER-REVIEWED STUDY OF MORE THAN 10,000 PCR RESULTS
Aspirin may protect against C****-**, Israeli research finds
People who take small doses are 29% less likely than others to test positive, researchers say; those who do get C***D recover faster, and with reduced aftereffects.
https://www.timesofisrael.com/aspirin-may-protect-against-c****-**-israeli-research-finds/Brief Summary:
C****-** has a high infection rate and mortality, and serious complications such as heart injury cannot be ignored. Cardiac dysfunction occurred in C****-** patients, but the law and mechanism of cardiac dysfunction remains unclear. The occurrence of progressive inflammatory factor storm and coagulation dysfunction in severe and fatal cases of NCP points out a new direction for reducing the incidence of severe and critically ill patients, shortening the length of duration in severe and critically ill patients and reducing the incidence of complications of cardiovascular diseases. Aspirin has the triple effects of inhibiting v***s replication, anticoagulant and anti-inflammatory, but it has not received attention in the treatment and prevention of NCP. Although Aspirin is not commonly used in the guidelines for the treatment of NCP, it was widely used in the treatment and prevention of a variety of human diseases after its first synthesis in 1898. Subsequently, aspirin has been confirmed to have antiv***l effect on multiple levels. Moreover, one study has confirmed that aspirin can inhibit v***s replication by inhibiting prostaglandin E2 (PGE2) in macrophages and upregulation of type I interferon production. Subsequently, pharmacological studies have found that aspirin as an anti-inflammatory and analgesic drug by inhibiting cox-oxidase (COX). Under certain conditions, the platelet is the main contributor of innate immune response, studies have found that in the lung injury model in dynamic neutrophil and platelet aggregation.
In summary, the early use of aspirin in c****-** patients, which has the effects of inhibiting v***s replication, anti-platelet aggregation, anti-inflammatory and anti-lung injury, is expected to reduce the incidence of severe and critical patients, shorten the length of hospital duration and reduce the incidence of cardiovascular complications.
https://clinicaltrials.gov/ct2/show/NCT04365309The NIH, CDC and the MSM should be "Shouting this from the Mountian Tops", ask yourself why they aren't?